Adial Pharmaceuticals, Inc
ADILStock
$2.79−98.86%52W
Market Cap$5.82M
P/E—
Div yield—
Beta-673.92
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-106.93%
Price vs S&P 500 (4W)-6.62%
VGM Score35.82
Market Capitalization$5.82M
Earnings Surprise History
Q1 26-1.48est. -2.78
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.13
4.13
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ADILAdial Pharmaceuticals, Inc | — | — | D | $2.79 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing prescription treatments for addiction and related disorders. Its lead candidate, AD04, is an ondansetron-based therapy for alcohol use disorder, designed to address a significant unmet medical need in addiction medicine.